* patients with bmi ≥30 and/or body weight \< 40kg * patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit. * patients who cannot be administered intramuscularly to bilateral ventro-gluteal area. * patients with uncontrolled respiratory disease other than covid-19 pneumonia (i.e. copd, asthma, cystic fibrosis, etc.) * patients who have active malignancy, history of active malignancy or chemotherapy within 1 year from the screening.

* patients with bmi ≥30 and/or body weight \< 40kg * patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit. * patients who cannot be administered intramuscularly to bilateral ventro-gluteal area. * patients with uncontrolled respiratory disease other than covid-19 pneumonia (i.e. copd, asthma, cystic fibrosis, etc.) * patients who have active malignancy, history of active malignancy or chemotherapy within 1 year from the screening.

patients with bmi ≥30 and/or body weight < 40kg patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit. patients who cannot be administered intramuscularly to bilateral ventro-gluteal area. patients with uncontrolled respiratory disease other than covid-19 pneumonia (i.e. copd, asthma, cystic fibrosis, etc.) patients who have active malignancy, history of active malignancy or chemotherapy within 1 year from the screening.

patients with bmi ≥30 and/or body weight < 40kg patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit. patients who cannot be administered intramuscularly to bilateral ventro-gluteal area. patients with uncontrolled respiratory disease other than covid-19 pneumonia (i.e. copd, asthma, cystic fibrosis, etc.) patients who have active malignancy, history of active malignancy or chemotherapy within 1 year from the screening.

patients with bmi ≥30. patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit. patients who cannot be administered intramuscularly to bilateral ventro-gluteal area.

patients with bmi ≥30. patients receiving or who have received antiviral therapy and antiretroviral therapy within 28 days prior to the screening visit. patients who cannot be administered intramuscularly to bilateral ventro-gluteal area.